Pharmaceutical lobbying spend rose 32% in '07

Share this article:
Pharmaceutical industry spending on lobbying rose 32% to $168 million in 2007, according to the Center for Public Integrity.

With the FDA Amendments Act and other contentious legislation affecting the industry in play, PhRMA was the top industry spender, shelling out nearly $23 million on lobbying – a 26% increase in spending over 2006. The trade group and its allies got their money's worth, as restrictions on marketing were scuttled.

Among individual companies, Amgen was the biggest spender, dropping $16.2 million on lobbying amid government investigations centered on its anemia franchise. Next up was Pfizer, at $13.8 million, followed by Roche ($9 million), Sanofi-Aventis ($8.4 million), GlaxoSmithKline ($8.2 million) and Johnson & Johnson ($7.7 million).

Altogether, the industry has spent more than $1 billion on lobbying over the past decade, said the Center for Public Integrity, which based its analysis on Senate Office of Public Records data. The group's report is titled Pushing prescriptions: how the drug industry sells its agenda at your expense.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.